Large gap with delayed quotes
|
Last quote
12/26/2024 -
20:00:00
|
Bid
12/27/2024 -
07:00:09
|
Bid Volume |
Ask
12/27/2024 -
07:00:09
|
Ask Volume |
|---|---|---|---|---|
|
67.02
+0.39
(
+0.59% )
|
63.91
|
100 |
67.99
|
100 |
Analysis date: 24.12.2024
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 06.09.2024.
Interest
Weak
Weak
Weak interest since 17.12.2024.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 25.10.2024 at a price of 69.73.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 06.09.2024), the stock traded below its moving average. The confirmed Technical Reverse (Tech Reverse + 1.75%) point is
4wk Rel Perf
1.49%
1.49%
The four week relative overperformance versus SP500 is 1.49%.
Sensibility
Middle
Middle
Moderate, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.08%.
Mkt Cap in $bn
12.63
12.63
With a market capitalization >$8bn, BIOMARIN PHARMA is considered a large-cap stock.
G/PE Ratio
1.82
1.82
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
15.95
15.95
The estimated PE is for the year 2026.
LT Growth
29.02%
29.02%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
20
20
Over the last seven weeks, an average of 20 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
48
48
For 1% of index variation, the stock varies on average by 0.48%.
Correlation
0.22
0.22
Stock movements are strongly independent of index variations.
Value at Risk
10.75
10.75
The value at risk is estimated at USD 10.75. The risk is therefore 16.13%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2003
21.05.2003